| Hazard Information | Back Directory | [Uses]
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[1][2][3]. | [References]
[1] Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.
[2] Cai Jiaqiang, et al. Antibody-drug conjugate containing BCL-2 family proteolysis agent, preparation method therefor, and use thereof. WO2024153185. 2024.07.25.
[3] Nathanson, David A., et al. Combination therapy for treating glioblastoma. WO2022231996. 2022.11.03. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|